Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
- PMID: 18806775
- PMCID: PMC4084721
- DOI: 10.1038/nature07284
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Abstract
Glycogen synthase kinase 3 (GSK3) is a multifunctional serine/threonine kinase that participates in numerous signalling pathways involved in diverse physiological processes. Several of these pathways are implicated in disease pathogenesis, which has prompted efforts to develop GSK3-specific inhibitors for therapeutic applications. However, before now, there has been no strong rationale for targeting GSK3 in malignancies. Here we report pharmacological, physiological and genetic studies that demonstrate an oncogenic requirement for GSK3 in the maintenance of a specific subtype of poor prognosis human leukaemia, genetically defined by mutations of the MLL proto-oncogene. In contrast to its previously characterized roles in suppression of neoplasia-associated signalling pathways, GSK3 paradoxically supports MLL leukaemia cell proliferation and transformation by a mechanism that ultimately involves destabilization of the cyclin-dependent kinase inhibitor p27(Kip1). Inhibition of GSK3 in a preclinical murine model of MLL leukaemia provides promising evidence of efficacy and earmarks GSK3 as a candidate cancer drug target.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4084721/bin/nihms-592674-f0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4084721/bin/nihms-592674-f0002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4084721/bin/nihms-592674-f0003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4084721/bin/nihms-592674-f0004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4084721/bin/nihms-592674-f0005.gif)
Similar articles
-
Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue.Clin Cancer Res. 2009 Apr 15;15(8):2620-9. doi: 10.1158/1078-0432.CCR-08-2473. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318494
-
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.Mol Cancer Ther. 2016 Jul;15(7):1485-1494. doi: 10.1158/1535-7163.MCT-15-0566. Epub 2016 May 9. Mol Cancer Ther. 2016. PMID: 27196775 Free PMC article.
-
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.Cancer Cell. 2010 Dec 14;18(6):606-18. doi: 10.1016/j.ccr.2010.10.032. Cancer Cell. 2010. PMID: 21156284
-
Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β-catenin pathway.Curr Opin Hematol. 2012 Jul;19(4):280-6. doi: 10.1097/MOH.0b013e3283545615. Curr Opin Hematol. 2012. PMID: 22525581 Review.
-
GSK-3 as a novel prognostic indicator in leukemia.Adv Biol Regul. 2017 Aug;65:26-35. doi: 10.1016/j.jbior.2017.05.001. Epub 2017 May 8. Adv Biol Regul. 2017. PMID: 28499784 Review.
Cited by
-
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.Cancer Res Commun. 2024 Feb 16;4(2):431-445. doi: 10.1158/2767-9764.CRC-23-0379. Cancer Res Commun. 2024. PMID: 38284896 Free PMC article.
-
Signaling pathways governing the behaviors of leukemia stem cells.Genes Dis. 2023 Mar 23;11(2):830-846. doi: 10.1016/j.gendis.2023.01.008. eCollection 2024 Mar. Genes Dis. 2023. PMID: 37692500 Free PMC article. Review.
-
The Effect of Sargassum Angustifolium-derived AgNPs on Apoptosis-associated Genes in Acute Lymphoblastic Leukemia Cells.Asian Pac J Cancer Prev. 2023 Aug 1;24(8):2691-2696. doi: 10.31557/APJCP.2023.24.8.2691. Asian Pac J Cancer Prev. 2023. PMID: 37642055 Free PMC article.
-
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664. Pharmaceutics. 2023. PMID: 36839989 Free PMC article. Review.
-
Lithium: A Promising Anticancer Agent.Life (Basel). 2023 Feb 15;13(2):537. doi: 10.3390/life13020537. Life (Basel). 2023. PMID: 36836894 Free PMC article. Review.
References
-
- Kim L, Kimmel AR. GSK3 at the edge: regulation of developmental specification and cell polarization. Curr. Drug Targets. 2006;7:1411–1419. - PubMed
-
- Cohen P, Frame S. The renaissance of GSK3. Nature Rev. Mol. Cell Biol. 2001;2:769–776. - PubMed
-
- Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 1987;262:14042–14048. - PubMed
-
- Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–789. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous